Gastric Cancer Market Report 2025

This Gastric Cancer market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.65 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth during the historic period can be attributed to factors such as an increasing geriatric population, rising healthcare awareness, a growing number of genetic mutations, the adoption of unhealthy lifestyles, and heightened awareness about cancer.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. In the forecast period, growth is expected due to rising obesity rates, growing government initiatives, increased healthcare investments, a higher demand for oral drugs, and the expanding number of cancer treatment facilities. Key trends during this period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collaborations, and the development of advanced diagnostic tools.

The growing rates of obesity are expected to drive the expansion of the gastric cancer market in the future. Obesity is a medical condition characterized by excessive body fat, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The increase in obesity rates can be attributed to factors such as poor dietary habits, lack of exercise, sedentary lifestyles, environmental influences, and genetic factors. Excess body fat, especially visceral fat around the abdomen, is linked to an elevated risk of developing gastric cancer. Obesity causes chronic inflammation and metabolic imbalances, both of which are associated with cancer development, thereby contributing to a higher demand for gastric cancer treatments. For example, the World Health Organization reported in March 2024 that approximately 1 in 8 people globally were living with obesity in 2022. Around 2.5 billion adults aged 18 and older were considered overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 were overweight, and more than 390 million children and adolescents aged 5-19 were overweight, including 160 million living with obesity. As a result, rising obesity rates are fueling the demand for gastric cancer treatments.

Leading companies in the gastric cancer market are focused on developing advanced solutions, such as companion diagnostic assays, to ensure personalized treatment. Companion diagnostic assays are tests that identify patients likely to benefit from specific treatments based on certain biomarkers. In October 2024, F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay. This was the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by detecting CLDN18 protein variants, particularly CLDN18.2. This test utilizes the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, advancing personalized healthcare and expanding treatment options for gastric and GEJ adenocarcinoma patients.

In June 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela Therapeutics to diversify its pipeline and address multiple therapeutic areas. The deal adds four clinical-stage assets, including two late-stage registration assets, enhancing the combined entity’s potential. This strategic move strengthens Panbela's position in high-potential therapeutic areas. Cancer Prevention Pharmaceuticals Inc. is a biotechnology company in the US that develops therapeutics for gastric cancer treatment.

Major players in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., and AROG Pharmaceuticals Inc.

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastric cancer is a malignant tumor that begins in the stomach lining, often starting in the mucosa, the innermost layer of the stomach. If left untreated, it can spread to deeper layers, surrounding tissues, or distant organs. Common risk factors for the disease include chronic infection with Helicobacter pylori, smoking, heavy alcohol consumption, an unhealthy diet, and genetic factors.

The main types of gastric cancers include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma, the most prevalent type, originates in the glandular cells of the stomach lining. Diagnosis is typically made through endoscopy, biopsy, imaging tests, exploratory surgery, and other methods. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and more. These treatments are distributed through various channels, including hospital pharmacies, specialty and retail pharmacies, among others.

The gastric cancer market research report is one of a series of new reports that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.